Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V 12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

Provided is an isolated binding protein including an antigen binding domain binding to an NS1 protein. The binding protein can identify and bind to the NS1 protein so as to detect dengue virus.

This disclosure provides a method for polymerizing polyphenols to provide polyphenol polymers using peroxidase and similar catalysis. In various aspects, it provides a method for polymerizing a polyphenol (e.g., polydopamine or a derivative or conjugate thereof) on a surface comprising polymerizing the polyphenol, a method for detecting an analyte comprising polymerizing a polyphenol, and an assay kit comprising a polyphenol (e.g., dopamine or a dopamine derivative). In one embodiment, a method for polymerizing a polyphenol includes contacting the polyphenol and an oxidant with an enzyme having peroxidase-like activity, under conditions sufficient to polymerize the polyphenol. In another embodiment, a method for depositing a polyphenol polymer (e.g., a polydopamine) includes providing, at a target site, an enzyme having peroxidase-like activity immobilized at the surface; and polymerizing, at the target site, a polyphenol in the presence of an oxidant and the enzyme to provide the polyphenol polymer, deposited on the surface.

Disclosed are real-time insect surveillance sensor devices and methods that use a colorimetric readout for detecting insect disease vectors (such as mosquitoes which can transmit pathogens such as DENV, CHIKV, and ZIKV). The method involves an attractive or feeding solution combined with detector conjugates. The conjugate can specifically detect proteins present in insect saliva and/or proteins specific to mosquito-borne pathogens.

The present disclosure is directed to compositions (e.g., multianalyte immunoassays) for detecting multiple Zika virus antibodies in a biological sample. Also disclosed herein are methods for identifying suitable donors for preparing a Zika virus hyperimmune composition. Methods for selectively detecting Zika virus antibodies in biological samples that may contain other flavivirus antibodies are also provided. Methods of treating, preventing, or reducing the risk of a Zika virus infection are also provided.

Compositions including a virus-like particle (VLP)-based vaccine displaying a portion of ZIKV envelope protein (E) domain III (DIII) and a portion of ZIKV envelope protein (E) and related methods are disclosed herein. Further, compositions including vaccines comprising a portion of ZIKA virus E protein, wherein the portion of ZIKA virus E protein is either a full-length version of ZIKA virus E protein or a functionally equivalent version of the full-length ZIKA virus E protein, are disclosed.

The instant invention describes a virus reduction neutralization test (VRNT) which is a rapid, high throughput alternative to current standard low throughput and laborious neutralization assays. The VRNT utilizes imaging cytometry to count virus-infected cells at about one day post-infection (thus eliminating the wait time other assays employ allowing for viral infection cell to cell), reducing overall assay time and increasing throughput at least 15-fold.

Disclosed are compositions and methods for the detection of a flavivirus infection. In some embodiments, the method comprises detecting a recent flavivirus infection by measuring the amount of anti-NS1 IgG3. In other embodiments, the method comprises detecting a prior Dengue virus infection in a subject previously immunized with a Dengue virus vaccine comprising one or more non-Dengue flavivirus proteins.

A method for providing immunoassay test results includes collecting at least one biologic with a testing device, conjugating the biologic with particles on a conjugate pad of a test strip to create an immune complex, binding antigens or antibodies of the immune complex to antigens or antibodies of a test line, providing a software application to be stored on a mobile device having a camera; capturing an image of the testing device, including a color mosaic having at least one color value corresponding to a positive test result, comparing the color values of the test line image to the color values of the image of the color mosaic, determining if the color values of the image of the test line are within a predetermined range of the at least one color value of the image of the color mosaic corresponding to a positive test result; and presenting test results on the viewing screen.

A system for providing colorimetric and ratiometric comparison and quantification for medical test results, comprising a testing device including an alignment target and including a plurality of immunoassay test strips, the plurality of immunoassay test strips each including a test line and a control line, and a colorimetry device configured to operate with a mobile device, the mobile device including a camera and a software application stored thereon, wherein the software application provides executable instructions to detect color properties of a color of the test line and a color of a control line of at least one of the plurality of immunoassay test strips, determine a risk value for each of at least one disease risks tested using the biologic sample, wherein the risk value is a rating determined from the color properties of the color of the test line, and provide medical test results based on the risk value.